Abeona Therapeutics Inc. (ABEO)
| Market Cap | 328.86M +2.5% |
| Revenue (ttm) | 14.54M |
| Net Income | 66.14M |
| EPS | 0.91 |
| Shares Out | 57.00M |
| PE Ratio | 6.31 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,111,173 |
| Open | 5.76 |
| Previous Close | 5.65 |
| Day's Range | 5.68 - 5.86 |
| 52-Week Range | 4.00 - 7.54 |
| Beta | 1.35 |
| Analysts | Strong Buy |
| Price Target | 19.71 (+241.59%) |
| Earnings Date | May 13, 2026 |
About ABEO
Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platfor... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for ABEO stock is "Strong Buy." The 12-month stock price target is $19.71, which is an increase of 241.59% from the latest price.
News
Abeona Therapeutics Transcript: AGM 2026
The meeting addressed director elections, executive compensation, auditor ratification, and equity plan amendments. All proposals passed except the amendment to remove the advance notice provision for director nominations.
Abeona Therapeutics Slides: Investor presentation
Abeona Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on June 10, 2026.
Abeona Therapeutics Transcript: Jefferies Global Healthcare Conference 2026
ZEVASKYN's launch is progressing with growing patient access, strong demand, and expanding treatment center capacity. Payer coverage is robust, manufacturing is scaling, and ex-U.S. interest is high. Pipeline development continues, with profitability expected as patient volume increases.
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CLEVELAND, June 01, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awar...
Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences
CLEVELAND, May 26, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that members of its management team will participate in upcoming investor conferences in June 2026:
Abeona Therapeutics Earnings Call Transcript: Q1 2026
ZEVASKYN's commercial launch drove Q1 2026 revenue to $8.7M, with strong demand and broad payer coverage. Six QTCs are active, and profitability is targeted as early as June. The pipeline expanded with a novel PSMA CAR-T asset for prostate cancer, while ophthalmology programs were deprioritized.
Abeona Therapeutics Earnings release: Q1 2026
Abeona Therapeutics released its Q1 2026 earnings on May 13, 2026, summarizing the period's financial results.
Abeona Therapeutics Quarterly report: Q1 2026
Abeona Therapeutics has published its Q1 2026 quarterly earnings report on May 13, 2026.
Abeona Therapeutics Slides: Q1 2026
Abeona Therapeutics has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 13, 2026.
Abeona Therapeutics reports Q1 EPS (30c), consensus (39c)
Reports Q1 revenue $8.72M, consensus $4.94M. “We are excited that an increasing number of patients at our QTCs are getting scheduled for ZEVASKYN slots this quarter,” said Vish Seshadri, president…
Abeona Therapeutics® Reports First Quarter 2026 Results and Provides Pipeline Update
- Three patients treated with ZEVASKYN ® in Q1 2026 - - QTC network expands to six sites, with two new additions on the East Coast - - In-licensed radically novel engineered T-cell technology with ga...
Abeona Therapeutics® Announces Activation of Children's Hospital of Philadelphia as a New Qualified Treatment Center for ZEVASKYN®
CLEVELAND, May 11, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a commercial-stage biopharmaceutical company developing genetic medicines for serious diseases with high unmet need...
Abeona Therapeutics® Announces Date of First Quarter Financial Results
CLEVELAND, May 04, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it will host a conference call on Wednesday, May 13, 2026 at 8:30 a.m. ET to discuss its financial r...
Abeona Therapeutics Proxy statement: Proxy filing
Abeona Therapeutics filed a proxy statement on May 4, 2026, providing details for shareholder voting and corporate governance matters.
Abeona Therapeutics Proxy statement: Proxy filing
Abeona Therapeutics filed a proxy statement on April 27, 2026, providing details for shareholder voting and corporate governance matters.
Abeona Therapeutics Proxy statement: Proxy filing
Abeona Therapeutics filed a proxy statement on April 17, 2026, providing details for shareholder voting and corporate governance matters.
Abeona Therapeutics Slides: Corporate presentation
Abeona Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on April 14, 2026.
Abeona Therapeutics® Announces Appointment of Keith A. Goldan to its Board of Directors
CLEVELAND, April 07, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the appointment of Keith A. Goldan as a new independent member to its Board of Directors, effectiv...
Abeona Therapeutics® Announces New Qualified Treatment Center for ZEVASKYN® in New York
CLEVELAND, April 02, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced activation of NewYork-Presbyterian/Columbia University Irving Medical Center in New York, NY as th...
Abeona Therapeutics price target lowered to $20 from $27.50 at Alliance Global
Alliance Global lowered the firm’s price target on Abeona Therapeutics (ABEO) to $20 from $27.50 and keeps a Buy rating on the shares following FY25 results. Alliance Global told investors…
Abeona Therapeutics Earnings Call Transcript: Q4 2025
ZEVASKYN's commercial launch is ramping up with strong patient demand, robust payer coverage, and expanding treatment center network. 2025 saw a return to profitability driven by a major voucher sale, and operational execution in 2026 is expected to drive further growth.
Abeona Therapeutics Annual report: Q4 2025
Abeona Therapeutics has published its Q4 2025 annual report on March 17, 2026.
Abeona Therapeutics Earnings release: Q4 2025
Abeona Therapeutics released its Q4 2025 earnings on March 17, 2026, summarizing the period's financial results.
Abeona Therapeutics reports 2025 EPS $1.01 vs. ($1.55) last year
Reports 2025 revenue $5.8M, consensus $4.82M. “2026 is about building a steady cadence of biopsies and treatments,” said CEO Vish Seshadri. “We are focused on ensuring every ZEVASKYN patient has…
Abeona Therapeutics® Reports Full Year 2025 Financial Results and Corporate Updates
- First ZEVASKYN ® commercial patient treatment completed in December - - ZEVASKYN launch momentum building in first quarter 2026 – - $191.4M in cash, cash equivalents and short-term investments as of...